Business Context and Reporting Period
Company: Anika Therapeutics, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2000
Business Overview: Anika develops, manufactures, and commercializes therapeutic products based on hyaluronic acid (HA) for bone, cartilage, and soft tissue healing. Key products include ORTHOVISC (osteoarthritis), HYVISC (equine osteoarthritis), and AMVISC/AMVISC Plus (ophthalmic viscoelastic supplements). The company relies heavily on distribution partners, notably Bausch & Lomb Surgical and Zimmer, Inc.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2000 | Nine Months Ended Sep 30, 2000 |
|---|---|---|
| Total Revenue | $2,729,807 | $9,219,405 |
| Gross Profit (Loss) | $(74,478) | $2,759,535 |
| Net Loss | $(1,382,824) | $(2,165,400) |
| Loss Per Share (Basic) | $(0.14) | $(0.22) |
| Cash & Cash Equivalents | $5,678,470 | $5,678,470 (Balance Sheet) |
| Total Investments | $12,291,843 | $12,291,843 (Balance Sheet) |
| Working Capital | $20,530,021 | $20,530,021 (Calculated) |
| Accumulated Deficit | $(6,937,906) | $(6,937,906) |
Note: Working Capital calculated as Total Current Assets ($26,846,059) minus Total Current Liabilities ($6,316,038).
Material Changes vs. Prior Period
- Revenue Decline: Total revenue for the nine months ended September 30, 2000, decreased 7% to $9.22 million from $9.86 million in the prior year. Product revenue dropped 9% in the third quarter compared to the same period in 1999.
- Gross Margin Compression: The company reported a gross loss of $74,478 in the third quarter of 2000, a significant deterioration from a gross profit of $1.57 million in the prior year quarter. Gross margin percentage fell from 51% to negative 7% for the quarter. This was driven by lower unit prices under a new agreement with Bausch & Lomb and reduced manufacturing cost absorption due to scaled-back operations.
- Operating Expenses: Selling, general, and administrative (SG&A) expenses increased 53% in the third quarter to $1.09 million, primarily due to higher professional fees. Research and development expenses decreased 57% to $516,171 due to lower clinical trial costs.
- Cash Flow: Net cash used in operating activities was $2.31 million for the nine months ended September 30, 2000, compared to $882,159 provided by operating activities in the prior year period. This shift was largely due to the net loss and inventory buildup.
Guidance, Outlook, Risks, and Unusual Items
Management Commentary and Outlook
- Revenue Recognition Restatement: The company restated 1998 and 1999 results following an SEC inquiry regarding revenue recognition for sales to Zimmer. This resulted in a cumulative charge of $3.625 million in 1999 and significant deferred revenue balances.
- Zimmer Termination: On November 10, 2000, Anika terminated its distribution agreement with Zimmer. Approximately $4.3 million of previously deferred revenue is expected to be recognized in the fourth quarter of 2000. However, future revenue from ORTHOVISC is uncertain as the company seeks new partners.
- Bausch & Lomb Agreement: A new seven-year supply agreement with Bausch & Lomb Surgical (effective Jan 1, 2001) includes retroactive price reductions. Management expects revenue and gross margins from this partner to decrease through mid-2001.
- Liquidity: With approximately $18 million in cash and investments, the company expects to fund operations through much of 2001 without additional financing, though future capital needs depend on clinical trial progress and market acceptance.
Risks and Contingencies
- SEC Investigation: The SEC has issued a formal order of investigation regarding historical revenue recognition. The outcome is unpredictable.
- Securities Litigation: Three consolidated class-action lawsuits have been filed alleging material misrepresentations regarding revenue recognition. The company plans to defend vigorously.
- Regulatory Hurdles: The Phase III clinical trial for ORTHOVISC did not show sufficient efficacy to support FDA approval. Further trials are planned, but approval is not guaranteed. ORTHOVISC remains limited to investigational use in the U.S.
- Customer Concentration: Bausch & Lomb Surgical accounted for 58% of product revenue for the nine months ended September 30, 2000. The Turkish distributor (Biomeks) accounted for 23% and is seeking renegotiation due to pricing pressures.
Investor Verification Checklist
- Deferred Revenue Recognition: Verify the timing and amount of the $4.3 million revenue recognition expected in Q4 2000 following the Zimmer termination.
- SEC Investigation Status: Monitor updates on the SEC formal order of investigation regarding revenue recognition policies.
- Class Action Litigation: Track the progress of the consolidated securities class-action lawsuit and potential settlement or judgment impacts.
- ORTHOVISC Clinical Trials: Confirm the design, timeline, and results of the additional clinical trials required for FDA Pre-Market Approval (PMA).
- Bausch & Lomb Pricing Impact: Assess the long-term impact of the retroactive price reductions on gross margins and the ability to offset these with volume increases.
- Turkish Market Stability: Evaluate the outcome of renegotiations with the Turkish distributor and the risk of revenue loss in that region.